Spark Therapeutics Inc (NASDAQ:ONCE) has been assigned a consensus recommendation of “Buy” from the twenty-two brokerages that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and eighteen have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $90.68.

Several equities research analysts recently weighed in on the company. Evercore ISI assumed coverage on Spark Therapeutics in a report on Wednesday, August 16th. They set an “in-line” rating and a $83.00 price target for the company. Cantor Fitzgerald set a $105.00 price objective on Spark Therapeutics and gave the stock a “buy” rating in a research report on Monday. BMO Capital Markets set a $89.00 price objective on Spark Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 10th. Barclays began coverage on Spark Therapeutics in a research report on Wednesday, September 6th. They issued an “overweight” rating and a $104.00 price objective for the company. Finally, Royal Bank Of Canada began coverage on Spark Therapeutics in a research report on Thursday, September 14th. They issued an “outperform” rating and a $100.00 price objective for the company.

Spark Therapeutics (ONCE) traded up $2.82 during mid-day trading on Monday, hitting $73.38. The stock had a trading volume of 669,500 shares, compared to its average volume of 398,833. Spark Therapeutics has a 1-year low of $47.03 and a 1-year high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The company had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. During the same period in the prior year, the business earned ($1.07) earnings per share. Spark Therapeutics’s revenue for the quarter was up 45.8% compared to the same quarter last year. sell-side analysts predict that Spark Therapeutics will post -7.6 EPS for the current fiscal year.

In other news, Director Hospital Of Philade Children’s sold 1,000,000 shares of the firm’s stock in a transaction on Thursday, September 21st. The stock was sold at an average price of $84.63, for a total value of $84,630,000.00. Following the completion of the transaction, the director now owns 3,928,707 shares in the company, valued at $332,486,473.41. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Daniel Faga sold 6,000 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $82.50, for a total value of $495,000.00. Following the completion of the transaction, the insider now owns 6,000 shares of the company’s stock, valued at approximately $495,000. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,074,809 shares of company stock valued at $90,304,385. Company insiders own 7.30% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. increased its position in Spark Therapeutics by 15.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after purchasing an additional 241,016 shares in the last quarter. BlackRock Inc. increased its position in Spark Therapeutics by 11.6% during the 2nd quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock worth $122,689,000 after purchasing an additional 213,520 shares in the last quarter. TIAA CREF Investment Management LLC increased its position in Spark Therapeutics by 20.3% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 62,480 shares of the biotechnology company’s stock worth $3,733,000 after purchasing an additional 10,544 shares in the last quarter. Amundi Pioneer Asset Management Inc. purchased a new stake in Spark Therapeutics during the 3rd quarter worth about $5,286,000. Finally, Balyasny Asset Management LLC increased its position in Spark Therapeutics by 104.8% during the 2nd quarter. Balyasny Asset Management LLC now owns 59,400 shares of the biotechnology company’s stock worth $3,549,000 after purchasing an additional 30,400 shares in the last quarter. Institutional investors and hedge funds own 94.94% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/11/spark-therapeutics-inc-once-receives-consensus-rating-of-buy-from-brokerages.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.